Want to see VVOS full AI Analyst Report?
VVOS Stock Chart & Stats
$2.22
-$0.06(-1.47%)
At close: 4:00 PM EST
$2.22
-$0.06(-1.47%)
Day’s Range― - ―
52-Week Range$0.38 - $5.95
Previous CloseN/A
Volume144.69K
Average Volume (3M)421.86K
Market Cap
$5.74M
Enterprise Value$27.30
Total Cash (Recent Filing)$2.11M
Total Debt (Recent Filing)$12.27M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 19, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding13,894,600
10 Day Avg. Volume324,525
30 Day Avg. Volume421,860
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-14.00
Price to Sales (P/S)1.20
P/FCF Ratio-1.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.93Price Target Upside-13.29% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.41
Revenue Forecast (FY)$23.25M
Bulls Say, Bears Say
Bulls Say
Improving Revenue & MarginsSustained revenue growth with a ~62% gross margin shows the core appliance and service offering can generate strong product-level profitability. That durable margin profile supports long-term operating leverage as patient volumes and higher‑margin services scale, improving contribution economics.
Rising Patient Volume & Provider ProductivityA 72% increase in completed appointments and documented provider productivity gains indicate scalable downstream demand and better per-provider economics. As trained providers increase throughput, revenue per practice can rise materially, making growth less reliant on raw marketing spend and more on provider training.
Strategic Partnerships & New Service LinesThe AIM Florida JV plus planned pediatric and insomnia programs diversify revenue beyond appliance sales into higher‑margin recurring services. Physician-aligned ventures and specialty referrals broaden referral sources and create potential site-level economics (~50% contribution), supporting longer-term, service-driven growth.
Bears Say
Stressed Balance SheetNegative shareholders' equity and meaningful debt materially constrain financial flexibility and increase the risk of further dilution or restructurings. This structural weakness limits ability to invest in scaling operations and raises the likelihood of creditor-driven terms that could affect governance and long-term strategy.
Persistent Cash Burn & Low LiquidityLarge negative operating and free cash flow, combined with a reported ~$2.1M cash balance, make the business dependent on external financing to execute strategy. Reliance on equity or debt raises dilutes holders or changes capital structure, and creates execution risk if markets or lenders tighten over the medium term.
High Operating Costs & LossesA sharp rise in G&A (to $9.0M) and persistent operating losses (EBIT materially negative) reflect elevated fixed and integration costs from acquisitions and expansions. Until overhead is reined in or scale materially improves, profitability remains elusive despite better gross margins, hampering durable cash generation.
Vivos Therapeutics News
VVOS FAQ
What was Vivos Therapeutics’s price range in the past 12 months?
Vivos Therapeutics lowest stock price was $0.38 and its highest was $5.95 in the past 12 months.
What is Vivos Therapeutics’s market cap?
Vivos Therapeutics’s market cap is $5.74M.
When is Vivos Therapeutics’s upcoming earnings report date?
Vivos Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 32 days.
How were Vivos Therapeutics’s earnings last quarter?
Currently, no data Available
Is Vivos Therapeutics overvalued?
According to Wall Street analysts Vivos Therapeutics’s price is currently Overvalued.
Does Vivos Therapeutics pay dividends?
Vivos Therapeutics does not currently pay dividends.
What is Vivos Therapeutics’s EPS estimate?
Vivos Therapeutics’s EPS estimate is -0.39.
How many shares outstanding does Vivos Therapeutics have?
Vivos Therapeutics has 13,894,600 shares outstanding.
What happened to Vivos Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vivos Therapeutics?
Currently, no hedge funds are holding shares in VVOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivos Therapeutics
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
VVOS Stock 12 Month Forecast
Average Price Target
$1.93
▼(-13.29% Downside)
Technical Analysis
Iridex
―
Co-Diagnostics
―
Adagio Medical Holdings
―
Envoy Medical
―
Nexalin Technology, Inc.
―
Ownership Overview
9.74% Insiders
2.26% Mutual Funds
0.26% Other Institutional Investors
87.31% Public Companies and
Individual Investors